TARDBP and metabolic syndrome: Also, the variability in MRI scanners and field strengths were potential sources of bias and the patients included in our sample had incomplete clinical information on other comorbidities that could be associated with brain atrophy and microangiopathy, such as hypertension or dyslipidemia, or on other neuropathologic features, such as TAR DNA-binding protein 43 pathology.